AIM: To evaluate the efficacy of L-carnitine on alleviating anemia, thrombocytopenia and leukopenia, and minimizing dose reductions in patients with chronic hepatitis C virus (HCV) in treatment with Interferon α (IFN-α) plus ribavirin. METHODS:Sixty-nine patients with chronic hepatitis C were enrolled in the study and divided into two groups. group A (n = 35) received Peg-IFN-α 2b plus ribavirin plus L-carnitine, and group B (n = 34) received Peg-IFN-α and ribavirin for 12 mo. All patients underwent laboratory investigations including: red cell count, hemoglobin, white cell count, platelets, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and viremia. RESULTS: After 12 mo in group A compared to group B we observed significant differences in AST 108.8 vs 76.8 (IU/L; P < 0.001), ALT 137.9 vs 112.3 (IU/L; P < 0.001), viremia 4.04 vs 2.36 (× 10(6) copies/mL; P < 0.001), Hb 1 vs 3.5 (g/dL; P < 0.05), red blood cells 0.3 vs 1.1 (× 10(12)/L; P < 0.001), white blood cells 1.5 vs 3 (× 10(9)/L; P < 0.001) and platelets 86 vs 85 (× 10(9)/L; P < 0.001). The end treatment responders were 18 vs 12 (60% vs 44%) and the non responders were 12 vs 15 (40% vs 50%) [odds ratio (OR) 1.65, 95% CI = 0.65-5.37, P < 0.05]. In group A compared to group B there was a significant improvement of sustained virological response in 15 vs 7 patients (50% vs 25%), while the relapsers were 3 vs 5 (10% vs 18%) (OR 3.57, 95% CI = 0.65-19.3, P < 0.001). CONCLUSION: L-carnitine supplementations modulate erythropoiesis, leucopoiesis and thrombocytopoiesis, and may be useful in patients treated for HCV. L-carnitine treatment offers the possibility of achieving a sustained virological response while preventing overtreatment.
RCT Entities:
AIM: To evaluate the efficacy of L-carnitine on alleviating anemia, thrombocytopenia and leukopenia, and minimizing dose reductions in patients with chronic hepatitis C virus (HCV) in treatment with Interferon α (IFN-α) plus ribavirin. METHODS: Sixty-nine patients with chronic hepatitis C were enrolled in the study and divided into two groups. group A (n = 35) received Peg-IFN-α 2b plus ribavirin plus L-carnitine, and group B (n = 34) received Peg-IFN-α and ribavirin for 12 mo. All patients underwent laboratory investigations including: red cell count, hemoglobin, white cell count, platelets, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and viremia. RESULTS: After 12 mo in group A compared to group B we observed significant differences in AST 108.8 vs 76.8 (IU/L; P < 0.001), ALT 137.9 vs 112.3 (IU/L; P < 0.001), viremia 4.04 vs 2.36 (× 10(6) copies/mL; P < 0.001), Hb 1 vs 3.5 (g/dL; P < 0.05), red blood cells 0.3 vs 1.1 (× 10(12)/L; P < 0.001), white blood cells 1.5 vs 3 (× 10(9)/L; P < 0.001) and platelets 86 vs 85 (× 10(9)/L; P < 0.001). The end treatment responders were 18 vs 12 (60% vs 44%) and the non responders were 12 vs 15 (40% vs 50%) [odds ratio (OR) 1.65, 95% CI = 0.65-5.37, P < 0.05]. In group A compared to group B there was a significant improvement of sustained virological response in 15 vs 7 patients (50% vs 25%), while the relapsers were 3 vs 5 (10% vs 18%) (OR 3.57, 95% CI = 0.65-19.3, P < 0.001). CONCLUSION:L-carnitine supplementations modulate erythropoiesis, leucopoiesis and thrombocytopoiesis, and may be useful in patients treated for HCV. L-carnitine treatment offers the possibility of achieving a sustained virological response while preventing overtreatment.
Authors: M T Gallucci; R Lubrano; C Meloni; M Morosetti; S Manca di Villahermosa; P Scoppi; G Palombo; M A Castello; C U Casciani Journal: Clin Nephrol Date: 1999-10 Impact factor: 0.975
Authors: Yaser Abdallah; Dragan Gligorievski; Sascha A Kasseckert; Lukas Dieterich; Matthias Schäfer; Christoph R Kuhlmann; Thomas Noll; Heinrich Sauer; H Michael Piper; Claudia Schäfer Journal: Cardiovasc Res Date: 2006-11-23 Impact factor: 10.787
Authors: M Malaguarnera; A Laurino; I Di Fazio; G Pistone; M Castorina; N Guccione; L Rampello Journal: J Interferon Cytokine Res Date: 2001-05 Impact factor: 2.607
Authors: G Sener; E Ekşioğlu-Demiralp; M Cetiner; F Ercan; S Sirvanci; N Gedik; B C Yeğen Journal: Cell Biol Toxicol Date: 2006-01 Impact factor: 6.691
Authors: Dae Won Jun; Byung Ik Kim; Yong Kyun Cho; Hong Ju Kim; Young Oh Kwon; Soo Young Park; Sang Young Han; Yang Hyun Baek; Yong Jin Jung; Hwi Young Kim; Won Kim; Jeong Heo; Hyun Young Woo; Seong Gyu Hwang; Kyu Sung Rim; Jong Young Choi; Si Hyun Bae; Young Sang Lee; Young Suck Lim; Jae Youn Cheong; Sung Won Cho; Byung Seok Lee; Seok Hyun Kim; Joo Hyun Sohn; Tae Yeob Kim; Yong Han Paik; Ja Kyung Kim; Kwan Sik Lee Journal: Clin Mol Hepatol Date: 2013-06-27
Authors: Ricardo A Cruciani; Manuel Revuelta; Ella Dvorkin; Peter Homel; Pauline Lesage; Nora Esteban-Cruciani Journal: HIV AIDS (Auckl) Date: 2015-02-19